CLINICAL NEWS
Written in Blood
Encouraging Results from a
First-in-Human Trial of ACE910
to Treat Severe Hemophilia A
While patients with severe
hemophilia A have a higher risk
of bleeding complications than
patients with moderate or mild
hemophilia A, an investigational
bispecific antibody that mimics factor VIII (FVIII) could be
a safe and effective treatment
for these patients, according to
results of a first-in-human trial
recently published in Blood. The
pharmacokinetic and pharmacodynamics profile of ACE910
suggest that the drug has the
potential to reduce bleeding
frequency in patients with severe
hemophilia A to that of patients
with mild hemophilia A, even at
less-frequent dosing than existing FVIII and bypassing drugs.
“An important goal of hemophilia A treatment is maintenance
of FVIII:C ≥1 percent, which
reduces bleeding risk, particularly
at the joints,” the authors, led by
Naoki Uchida, MD, fr